Clinical Trial Detail

NCT ID NCT01084252
Title Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements yes
Sponsors Sanofi
Indications

acute myeloid leukemia

multiple myeloma

B-cell lymphoma

chronic lymphocytic leukemia

B-cell adult acute lymphocytic leukemia

Therapies

Isatuximab

Dexamethasone + Isatuximab

Age Groups: adult senior

Additional content available in CKB BOOST